Celgene Focuses On Deals, Pipeline As Post-Revlimid Future Draws Closer

Celgene's fourth quarter earnings report delivered no revenue surprises, but the company noted its pipeline progress and insisted that business development is the main priority for its $12bn in cash as it looks to bring in new assets that can boost post-Revlimid growth.

US-Money-and-Pills_V2_1200x675

Celgene Corp. has committed more than $10bn to two big acquisitions already this year, but the company's biggest priority for its $12bn in cash as of the end of 2017 is to do more deals, executives said during a Jan. 25 fourth quarter earnings conference call.

The primary concern for Celgene's investors is how the company will replace revenue from its top-selling product Revlimid (lenalidomide) when...

More from Earnings

More from Business